Global Opioid-Induced Constipation Market Overview:
Global Opioid-Induced Constipation Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2026-2035, Considering the Base Year As 2025.
Global Opioid-Induced Constipation Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Opioid-Induced Constipation involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Opioid-Induced Constipation Market:
The Opioid-Induced Constipation Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Opioid-Induced Constipation Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Opioid-Induced Constipation Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Opioid-Induced Constipation market has been segmented into:
Mu-opioid Receptor Antagonists
Chloride Channel-2 Activators
and Others
By Application, Opioid-Induced Constipation market has been segmented into:
Over The Counter
Prescription
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Opioid-Induced Constipation market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Opioid-Induced Constipation market.
Top Key Players Covered in Opioid-Induced Constipation market are:
AstraZeneca plc
Merck & Co Inc
Shionogi & Co Ltd
Mallinckrodt Pharmaceuticals
Bausch Health ( Salix Pharmaceutical Inc.)
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Opioid-Induced Constipation Market Type
4.1 Opioid-Induced Constipation Market Snapshot and Growth Engine
4.2 Opioid-Induced Constipation Market Overview
4.3 Mu-opioid Receptor Antagonists
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Mu-opioid Receptor Antagonists: Geographic Segmentation Analysis
4.4 Chloride Channel-2 Activators
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Chloride Channel-2 Activators: Geographic Segmentation Analysis
4.5 and Others
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 and Others: Geographic Segmentation Analysis
Chapter 5: Opioid-Induced Constipation Market Application
5.1 Opioid-Induced Constipation Market Snapshot and Growth Engine
5.2 Opioid-Induced Constipation Market Overview
5.3 Over The Counter
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Over The Counter: Geographic Segmentation Analysis
5.4 Prescription
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Prescription: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Opioid-Induced Constipation Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ASTRAZENECA PLC
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 MERCK & CO INC
6.4 SHIONOGI & CO LTD
6.5 MALLINCKRODT PHARMACEUTICALS
6.6 BAUSCH HEALTH ( SALIX PHARMACEUTICAL INC.)
Chapter 7: Global Opioid-Induced Constipation Market By Region
7.1 Overview
7.2. North America Opioid-Induced Constipation Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Mu-opioid Receptor Antagonists
7.2.2.2 Chloride Channel-2 Activators
7.2.2.3 and Others
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Over The Counter
7.2.3.2 Prescription
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Opioid-Induced Constipation Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Mu-opioid Receptor Antagonists
7.3.2.2 Chloride Channel-2 Activators
7.3.2.3 and Others
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Over The Counter
7.3.3.2 Prescription
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Opioid-Induced Constipation Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Mu-opioid Receptor Antagonists
7.4.2.2 Chloride Channel-2 Activators
7.4.2.3 and Others
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Over The Counter
7.4.3.2 Prescription
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Opioid-Induced Constipation Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Mu-opioid Receptor Antagonists
7.5.2.2 Chloride Channel-2 Activators
7.5.2.3 and Others
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Over The Counter
7.5.3.2 Prescription
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Opioid-Induced Constipation Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Mu-opioid Receptor Antagonists
7.6.2.2 Chloride Channel-2 Activators
7.6.2.3 and Others
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Over The Counter
7.6.3.2 Prescription
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Opioid-Induced Constipation Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Mu-opioid Receptor Antagonists
7.7.2.2 Chloride Channel-2 Activators
7.7.2.3 and Others
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Over The Counter
7.7.3.2 Prescription
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Opioid-Induced Constipation Scope:
|
Report Data
|
Opioid-Induced Constipation Market
|
|
Opioid-Induced Constipation Market Size in 2025
|
USD XX million
|
|
Opioid-Induced Constipation CAGR 2025 - 2032
|
XX%
|
|
Opioid-Induced Constipation Base Year
|
2024
|
|
Opioid-Induced Constipation Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
AstraZeneca plc, Merck & Co Inc, Shionogi & Co Ltd, Mallinckrodt Pharmaceuticals, Bausch Health ( Salix Pharmaceutical Inc.).
|
|
Key Segments
|
By Type
Mu-opioid Receptor Antagonists
Chloride Channel-2 Activators
and Others
By Applications
Over The Counter
Prescription
|
